Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $7.55 million versus the consensus estimate of $10.32 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.